The SYNERGY II Everolimus elutiNg stent In patients Older than 75 years undergoing coronary Revascularisation associated with a short dual antiplatelet therapy (SENIOR) trial: rationale and design of a large-scale randomised multicentre study.
about
The SYNERGY II Everolimus elutiNg stent In patients Older than 75 years undergoing coronary Revascularisation associated with a short dual antiplatelet therapy (SENIOR) trial: rationale and design of a large-scale randomised multicentre study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
The SYNERGY II Everolimus elut ...... randomised multicentre study.
@en
The SYNERGY II Everolimus elut ...... hort dual antiplatelet therapy
@nl
type
label
The SYNERGY II Everolimus elut ...... randomised multicentre study.
@en
The SYNERGY II Everolimus elut ...... hort dual antiplatelet therapy
@nl
prefLabel
The SYNERGY II Everolimus elut ...... randomised multicentre study.
@en
The SYNERGY II Everolimus elut ...... hort dual antiplatelet therapy
@nl
P2093
P356
P1476
The SYNERGY II Everolimus elut ...... e randomised multicentre study
@en
P2093
Aurès Chaïb
Isabelle Durand-Zaleski
Manel Sabaté
Marie-Claude Morice
Olivier Hanon
Olivier Varenne
Thomas Cuisset
Tian-Hai Koh
P304
P356
10.4244/EIJY15M12_02
P577
2017-01-01T00:00:00Z